Does insurance cover Wegovy in Florida?

If you’ve been prescribed a GLP-1 medication like Wegovy, Ozempic, or Mounjaro, you’re probably wondering: Will my insurance actually cover this? It’s a crucial question—these medications can cost over $1,000 per month without coverage, putting them out of reach for many people who could benefit.

The short answer? It depends. Coverage for GLP-1 medications is complicated, varies widely by insurance type and state, and often requires navigating prior authorization hurdles. But understanding the landscape can help you maximize your chances of approval—or find affordable alternatives if your claim gets denied.

This comprehensive guide breaks down exactly how insurance coverage works for Wegovy, Ozempic, and Mounjaro across commercial plans, Medicare, and Medicaid in 2025.

Understanding GLP-1 Medications: What’s the Difference?

Before diving into coverage, let’s clarify what these medications are and how they differ:

Ozempic (semaglutide) is FDA-approved for treating Type 2 diabetes. It helps lower blood sugar and has the side benefit of promoting weight loss. Many people use it off-label for weight management, though insurance rarely covers this use.

Wegovy (also semaglutide) is the same active ingredient as Ozempic but is specifically FDA-approved for chronic weight management in adults with obesity (BMI ≥30) or overweight adults (BMI ≥27) with at least one weight-related condition like high blood pressure or Type 2 diabetes.

Mounjaro (tirzepatide) is FDA-approved for Type 2 diabetes management. It’s a dual GIP/GLP-1 receptor agonist, which some studies suggest may be even more effective than semaglutide for weight loss. Its obesity-specific version is marketed as Zepbound.

The key takeaway: Insurance typically covers these medications only for their FDA-approved uses. That means Ozempic and Mounjaro are usually covered for diabetes, while Wegovy faces more barriers as a weight-loss medication.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

Commercial Insurance Coverage: The Mixed Bag

How Most Private Plans Handle GLP-1s

If you have employer-sponsored or marketplace health insurance, here’s what to expect:

For diabetes treatment: Ozempic and Mounjaro are generally covered as essential health benefits when prescribed for Type 2 diabetes. However, they’re typically placed on Tier 3 (non-preferred brand) or even Tier 4 (specialty), meaning higher copays or coinsurance—often 25-50% of the drug cost.

For weight loss: This is where it gets tricky. Many commercial plans exclude weight-loss medications entirely or impose strict limitations. According to recent surveys, fewer than half of large employer plans cover anti-obesity medications, viewing them as optional benefits due to their high cost.

When Wegovy is covered, insurers almost universally require prior authorization (PA). You’ll typically need to document:

• BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (hypertension, Type 2 diabetes, dyslipidemia, or obstructive sleep apnea)
• At least 6 months of documented supervised diet and lifestyle modification attempts
• No contraindications or history of medullary thyroid cancer or MEN2 syndrome
• Sometimes, evidence that you’ve tried (and failed on) older, cheaper weight-loss medications first

Major insurers like Aetna require these criteria and often limit initial approvals to 3-6 months, with continuation dependent on achieving at least 5% weight loss.

The Reality of Step Therapy

Step therapy requirements mean you must ‘step through’ less expensive treatment options before your insurer will pay for a costly medication. For weight loss, this often means:

1. Documenting intensive lifestyle interventions (diet counseling, exercise programs)
2. Sometimes trying older medications like phentermine or orlistat
3. Only then gaining approval for newer GLP-1s

For diabetes, step therapy typically requires trying metformin (and sometimes a second-line agent) before approval for GLP-1s—unless you have contraindications or clinical factors (like very high A1c or cardiovascular risk) that justify earlier use.

Common Denial Reasons and What to Do

Insurance denials for GLP-1 medications are frustratingly common. The most frequent reasons include:

Insufficient documentation: Your medical records may not clearly show the required BMI threshold, previous weight-loss attempts, or comorbidities. Solution: Ask your provider to submit comprehensive clinical notes documenting your weight history, failed diet attempts, and health conditions.

Not meeting medical necessity criteria: Perhaps your BMI is 28 with no documented comorbidity, falling just short of the 27+comorbidity threshold. Solution: Work with your doctor to document all relevant conditions (even borderline hypertension or prediabetes may qualify).

Plan exclusion: Some policies simply don’t cover ‘drugs for weight loss or weight management’ at all. Solution: Check your Summary of Benefits—if obesity treatment is excluded, appeals rarely succeed unless you can frame the prescription around another covered condition.

Off-label use denial: Requesting Ozempic for weight loss when you don’t have diabetes will almost always be denied. Solution: If you qualify for weight management therapy, ask about switching to Wegovy (the FDA-approved weight-loss version).

Failed step therapy: You haven’t tried required first-line treatments. Solution: Complete the required steps and resubmit with documentation.

The Appeals Process

If denied, don’t give up. Insurance appeals have a meaningful success rate when criteria are actually met but were poorly documented initially. Here’s how to appeal:

1. Request a formal denial letter explaining exactly why coverage was denied
2. Gather comprehensive documentation from your physician addressing each denial reason
3. Submit a letter of medical necessity from your provider explaining why this medication is clinically appropriate for you
4. Include supporting research showing efficacy for your specific condition
5. Follow your plan’s formal appeals process (usually outlined in your denial letter)

Most insurers respond to initial appeals within 5-7 business days for urgent requests, or up to 30 days for standard appeals. If the first appeal fails, you typically have the right to an external review by an independent medical expert.

Medicare Coverage: Limited and Conditional

The Medicare Dilemma

Here’s the frustrating reality: Medicare Part D does not cover medications prescribed solely for weight loss. This is due to a federal law (Social Security Act Section 1860D-2) that explicitly excludes ‘drugs used for weight loss’ from Part D coverage.

However, there’s a critical exception: Medicare will cover these medications for other FDA-approved indications.

For example:

• Ozempic and Mounjaro are covered under Part D for treating Type 2 diabetes
• Wegovy gained limited coverage in 2024 for reducing cardiovascular risk in obese patients with established heart disease—but not for weight loss as a primary indication

This creates a coverage gap for the millions of Medicare beneficiaries who could benefit from weight management but don’t have diabetes or documented cardiovascular disease.

Medicare Advantage Plans

Some Medicare Advantage (Part C) plans began offering limited obesity medication coverage in 2025 as a supplemental benefit. However, this varies dramatically by plan and typically comes with:

• High cost-sharing (often 25-50% coinsurance)
• Strict prior authorization requirements
• Coverage only for members meeting very specific criteria (often BMI ≥35 with multiple comorbidities)
• Annual or lifetime dollar limits on coverage

What Medicare Dual-Eligibles Should Know

If you have both Medicare and Medicaid (dual-eligible), Medicaid becomes your primary coverage for prescription drugs in some states. This means you might access Wegovy through Medicaid if your state covers it—but as we’ll see below, many states are now eliminating that coverage due to budget concerns.

Medicaid Coverage: A State-by-State Patchwork

The Federal Framework

Under federal law, states can choose whether to cover medications for weight loss in their Medicaid programs. The Social Security Act allows states to exclude ‘agents when used for weight loss’ from coverage.

As of late 2025, only about 13 states provide any Medicaid coverage for GLP-1 weight-loss medications—and several are now reversing course due to skyrocketing costs.

State-by-State Breakdown

California (Medi-Cal): Wegovy was added to the Medi-Cal formulary in 2025 with prior authorization, but coverage is ending January 1, 2026 for adults due to budget constraints. The state cited unsustainable spending growth—GLP-1 weight-loss drugs were projected to consume a massive portion of the pharmacy budget. Pediatric patients under 21 may still access coverage through EPSDT (Early and Periodic Screening, Diagnostic and Treatment) provisions.

Texas: Texas Medicaid does not cover any obesity medications for adults aged 21 and over. This policy has been in place since at least 2023, when the state explicitly excluded Wegovy, Saxenda, and similar drugs from the formulary. Pediatric exceptions may be considered on a case-by-case basis under EPSDT.

Florida: Like Texas, Florida Medicaid excludes all weight-loss drugs from coverage, invoking the federal optional exclusion. Only diabetes-indicated GLP-1s (like Ozempic for Type 2 diabetes) are covered.

New York: New York’s Medicaid program covers Wegovy with prior authorization under strict criteria. Patients must document BMI ≥30 (or ≥27 with comorbidities), previous lifestyle modification attempts, and age ≥18. Quantity limits typically allow 4 pens per 28 days.

Pennsylvania: Pennsylvania Medicaid added Wegovy coverage in 2023 with comprehensive PA requirements, including BMI thresholds, documented weight-related conditions, and evidence of diet/exercise attempts. However, the state announced in December 2025 that it will discontinue coverage for weight-loss GLP-1s in January 2026 to control costs. Patients with diabetes who previously used GLP-1s must try a preferred diabetes agent first before weight-loss formulations.

Illinois: Illinois Medicaid does not cover obesity medications as of 2025. While the state expanded coverage for state employees in 2023, this did not extend to Medicaid beneficiaries.

Medicaid Prior Authorization Requirements

States that do cover GLP-1 weight-loss drugs impose rigorous PA criteria, typically requiring:

• BMI documentation meeting FDA thresholds
• At least one (often multiple) obesity-related comorbidities
• Evidence of ≥6 months of supervised lifestyle intervention
• Regular monitoring and re-authorization based on weight-loss progress (usually requiring ≥5% weight loss to continue coverage)
• Age restrictions (most require age ≥18, though EPSDT may allow pediatric use)

The PA process can take 1-3 weeks, and denials are common if any documentation is incomplete.

The Budget Crisis

Why are states pulling back? The numbers are staggering. GLP-1 medications for weight loss were on track to become one of the top pharmacy expenditures in Medicaid programs that covered them. With per-member costs exceeding $15,000 annually and millions of potentially eligible beneficiaries, states faced budget impacts in the hundreds of millions—or even billions—of dollars. This financial pressure is driving the recent wave of coverage eliminations.

A Side-by-Side Comparison

What If Insurance Won’t Cover Your Medication?

Manufacturer Savings Programs

Both Novo Nordisk (Wegovy/Ozempic) and Eli Lilly (Mounjaro/Zepbound) offer significant discounts:

Novo Nordisk programs:

• Savings card for insured patients: Can reduce copays to as low as $0-$25 per month (up to $225 off monthly) for commercially insured patients
• Cash-pay program: Through NovoCare, self-pay patients can access Wegovy for $349/month (down from $1,350 list price)
• Patient assistance program: Free medication for uninsured or underinsured patients meeting income criteria (typically household income <400% of federal poverty level)

Eli Lilly programs:

• Savings card: $25/month for Mounjaro with commercial insurance and Type 2 diabetes diagnosis
• LillyDirect cash-pay: Zepbound single-dose vials now available for $299-$449/month depending on dosage
• Patient assistance: Free or low-cost medication for qualifying low-income patients

Important note: Manufacturer coupons and savings cards cannot be used with government insurance (Medicare, Medicaid, TRICARE). They’re designed for commercially insured or cash-paying patients only.

GoodRx and Discount Programs

In November 2025, GoodRx launched a groundbreaking partnership with Novo Nordisk offering:

• Introductory pricing: $199/month for the first two fills of Wegovy or Ozempic
• Ongoing pricing: Approximately $349/month thereafter (for most doses)
• No insurance required: Available to all cash-paying patients at participating pharmacies nationwide

This represents a roughly 70% discount from list prices and makes these medications substantially more accessible. The program also includes a $39/month telemedicine subscription for weight-loss support and prescribing services.

For Mounjaro, standard GoodRx coupons can bring costs down to around $1,000/month—still expensive, but better than full retail.

Generic Alternatives and Cautions

As of 2025, no FDA-approved generic versions of semaglutide or tirzepatide exist. Patents extend well into the 2030s.

Some patients have turned to compounded semaglutide or tirzepatide from specialty pharmacies or telehealth companies, typically at significantly lower prices ($200-$400/month). However, the FDA has issued warnings about these products:

• Compounded versions are not FDA-approved
• Quality, potency, and sterility are not guaranteed
• Dosing may be inaccurate
• Contamination risks exist

If cost is the only barrier and you’re considering compounded medications, discuss the risks thoroughly with your healthcare provider.

Other Weight-Loss Medication Options

If GLP-1s remain unaffordable, older weight-loss medications cost substantially less:

• Phentermine: $30-$50/month (generic stimulant appetite suppressant)
• Orlistat (Alli, Xenical): $50-$100/month (fat absorption blocker)
• Phentermine/topiramate (Qsymia): $150-$200/month (combination therapy)
• Naltrexone/bupropion (Contrave): $100-$150/month (combination therapy)

These medications are generally less effective than GLP-1s but may be covered more readily by insurance and are far more affordable out-of-pocket.

Telehealth, Insurance, and Weight Management

Insurance Coverage for Telehealth Visits

Good news: Most insurance plans now cover telehealth visits for weight management on par with in-person care. Since the COVID-19 pandemic, over 40 states have enacted telehealth parity laws requiring private insurers to cover virtual care equivalently to office visits.

This means:

• Nutritional counseling for obesity (an ACA-mandated preventive service) is covered via telehealth
• Weight-management medical visits with your PCP or specialist can be conducted virtually
• Copays for telehealth are typically the same as in-person visits

Important considerations:

• You usually need to use an in-network provider for coverage
• Some plans require live video (not just phone or text-based care)
• Coverage for telehealth-only companies varies—some plans contract with platforms, others don’t

How Klarity Health Fits In

Platforms like Klarity Health make accessing weight-management care more convenient than ever. With Klarity Health, you can:

• Connect with licensed providers who specialize in obesity medicine and metabolic health
• Get comprehensive evaluations and treatment plans from the comfort of home
• Receive prescriptions (when clinically appropriate) that can be filled at your local pharmacy
• Access transparent pricing—whether you’re using insurance or paying cash
• Choose the payment method that works for you: Klarity Health accepts both insurance and self-pay

If your insurance covers weight-management visits, you can often use those benefits with Klarity Health providers. And if you’re paying out-of-pocket for the visit, Klarity Health’s transparent pricing means no surprise bills. The prescribed medication can then be processed through your insurance (if covered) or via manufacturer programs and discount cards if you’re self-paying.

The platform’s provider availability is another advantage—appointments are often available within days rather than the weeks or months typical for specialist referrals, helping you start treatment faster.

Frequently Asked Questions

Does insurance cover Ozempic for weight loss if I don’t have diabetes?

Very rarely. Ozempic is FDA-approved only for Type 2 diabetes, so using it for weight loss is considered off-label. Most commercial insurers, Medicare, and Medicaid will deny coverage for off-label weight-loss use. If you qualify for weight-management medication (BMI ≥30 or ≥27 with comorbidities), ask your provider about Wegovy instead, which has FDA approval for obesity treatment and better coverage prospects.

Will my Medicare Advantage plan cover Wegovy?

It depends on your specific plan. Some Medicare Advantage plans added obesity medication as a supplemental benefit in 2025, but coverage varies widely. Check your plan’s formulary or call member services. Even when covered, expect high cost-sharing and strict prior authorization requirements. Traditional Medicare Part D does not cover Wegovy for weight loss.

Why was my Wegovy prior authorization denied?

Common reasons include: insufficient documentation of BMI or comorbidities, lack of evidence that you tried lifestyle modification for 6+ months, failure to meet step therapy requirements (trying cheaper options first), or your plan simply excluding weight-loss drugs altogether. Request a detailed denial explanation and work with your provider to address specific gaps for an appeal.

Can I use a manufacturer coupon with my insurance?

It depends. If you have commercial (private) insurance, manufacturer coupons can often be used alongside your insurance to reduce your copay—sometimes to $0. However, you cannot use manufacturer coupons with Medicare, Medicaid, TRICARE, or other government insurance programs; federal law prohibits this.

How long does prior authorization take?

Typical turnaround is 5-7 business days for standard requests, though urgent cases may be expedited to 24-72 hours. If additional information is requested or if you file an appeal, the process can extend to 2-4 weeks. Stay in contact with your provider’s office and insurance company to expedite the process.

What happens if I lose weight-loss drug coverage mid-treatment?

If your state Medicaid program or insurance plan eliminates coverage (as California and Pennsylvania are doing in 2026), you’ll need to either switch to self-pay options (using manufacturer programs or GoodRx discounts) or discontinue the medication. Talk to your provider about transitioning to affordable alternatives or transitioning off the medication safely to minimize weight regain.

Are GLP-1 medications covered for children and adolescents?

Wegovy is FDA-approved for adolescents aged 12+ with obesity. Coverage varies: some commercial plans cover pediatric use with PA, and Medicaid must provide coverage under EPSDT (Early and Periodic Screening, Diagnostic and Treatment) rules for members under 21 when medically necessary—even in states that exclude adult coverage. Medicare doesn’t apply to this age group.

Is there any way to get free GLP-1 medications?

Yes, through patient assistance programs (PAPs) offered by manufacturers. Both Novo Nordisk and Eli Lilly provide free medications to uninsured or significantly underinsured patients who meet income eligibility (typically <300-400% of federal poverty level). Applications require proof of income and lack of insurance coverage. Approvals usually provide 12 months of free medication.

Looking Ahead: Will Coverage Improve?

The landscape for GLP-1 weight-loss medication coverage is evolving rapidly—but not necessarily in a favorable direction for patients.

Short-term trends:

• More states are likely to drop Medicaid coverage due to budget pressures (following California and Pennsylvania’s lead)
• Commercial insurers are implementing stricter utilization management to control costs
• However, manufacturer pricing pressure and competition may drive continued price reductions for self-pay patients

Potential long-term changes:

• Proposed federal legislation could mandate Medicare Part D coverage for obesity medications, though this faces budget obstacles
• Biosimilar competition could emerge by 2030 as patents expire, dramatically lowering prices
• Oral GLP-1 formulations in development may be cheaper to manufacture and easier to cover
• Growing clinical evidence of cardiovascular and metabolic benefits beyond weight loss may expand covered indications

What you can do now:

• Advocate with your employer’s HR department to include weight-loss medications in your plan benefits
• Document everything—maintain thorough records of your weight, health conditions, and treatment attempts
• Stay informed about your plan’s formulary changes during open enrollment
• Consider all options—from telehealth providers to manufacturer programs to comprehensive lifestyle interventions

Taking the Next Step

Understanding insurance coverage is just the first step. If you’re struggling with obesity and considering GLP-1 medications:

1. Talk to your healthcare provider about whether these medications are clinically appropriate for you
2. Check your specific insurance formulary and PA requirements
3. Prepare comprehensive documentation before submitting prior authorization
4. Explore all cost-saving options if coverage is denied
5. Don’t delay treatment while fighting for coverage—your health is worth the investment

Whether your insurance covers these medications or you need to find alternative pathways, effective treatment for obesity is possible. The key is understanding your options, being persistent with the insurance process, and knowing where to turn for affordable access.

If you’re ready to start your weight management journey with expert guidance, Klarity Health’s experienced providers can help you navigate treatment options, insurance coverage, and create a personalized plan—all through convenient telehealth appointments. With provider availability that fits your schedule and transparent pricing whether you’re using insurance or self-pay, getting started is easier than you might think.

Research Currency Statement

Verified as of December 17, 2025

Formularies checked:

• Aetna Clinical Policy (May 2024) – www.aetna.com
• Cigna Formulary (April 2024) – www.singlecare.com
• Kaiser Permanente update (January 2025) – www.amwinsconnect.com
• Texas VDP criteria (March 2023) – www.texaschildrenshealthplan.org
• Pennsylvania Medicaid bulletin (August 2024) – www.phlp.org

Medicaid formularies verified:

• California DHCS (December 2025) – www.cmadocs.org
• Texas HHSC (March 2023) – www.texaschildrenshealthplan.org
• Florida (no Medicaid coverage per federal exclusion)
• New York NYRx PDL (October 2025) – solutionshortcut.com
• Pennsylvania DHS (December 2025) – www.wesa.fm
• Illinois HFS (no coverage as of 2025) – www.forbes.com

GoodRx prices as of December 2025:

• Novo Nordisk/NovoCare program (effective November 2025) – www.fiercepharma.com
• GoodRx press release (November 17, 2025) – www.businesswire.com
• Lilly pricing updates (December 2025) – www.fiercepharma.com

Coverage status and pricing are subject to change. Always verify current information with your specific insurance plan and pharmacy.

Source:

• https://www.aetna.com/products/rxnonmedicare/data/2024/WeightLoss%28BMI%2035%29GIP-GLP-1GLP-1AgonistsPAwithLimit6450-CUDR_05-2024.html#:~:text=%C2%B0Wegovy%3A%20Initial%20therapy%20DOA%3A%207,based%20on%20the%20following%20references
• https://www.singlecare.com/blog/cigna-prior-authorization-weight-loss/#:~:text=Cigna%20coverage%20criteria%20for%20GLP,drugs
• https://www.amwinsconnect.com/news/kaiser-permanenter-coverage-changes-glp-1-drugs-and-anti-obesity-medications-2025#:~:text=drugs%20and%20other%20AOMs%20will,with%20BMI%20less%20than%2040
• https://www.texaschildrenshealthplan.org/2023/04/28/provider-alert-non-formulary-requests-for-obesity-control-drugs#:~:text=for%20obesity%20control%20drugs%20for,Imcivree%2C%20Qysmia%2C%20Saxenda%20and%20Wegovy
• https://www.phlp.org/en/news/pennsylvania-medicaid-covers-newer-weight-loss-drugs#:~:text=Generally%2C%20to%20get%20these%20drugs,CDC%29%20charts
• https://www.cmadocs.org/newsroom/news/view/ArticleId/51074/GLP-1-medications-for-weight-loss-will-no-longer-be-covered-by-Medi-Cal#:~:text=What%20You%20Need%20to%20Know%3A,Cal%20managed%20care
• https://solutionshortcut.com/medicaid-drug-coverage-by-state-2025-2026-updates/#:~:text=VDP%20PDL%20%26%20criteria%3B%20last,com
• https://www.cmadocs.org/newsroom/news/view/ArticleId/51074/GLP-1-medications-for-weight-loss-will-no-longer-be-covered-by-Medi-Cal#:~:text=%2A%20Three%20GLP,covered%20after%20January%201%2C%202026
• https://www.forbes.com/sites/joshuacohen/2025/08/07/coverage-of-weight-loss-drugs-by-medicaid-plans-continues-to-lag/#:~:text=Medicaid%2C%20a%20federal,employees%20due%20to%20cost%20concerns
• https://www.fiercepharma.com/marketing/novo-unveils-newly-reduced-self-pay-prices-wegovy-ozempic-after-white-house-deal#:~:text=Novo%20revealed%20Monday%20that%20the,will%20still%20run%20for%20%24499